---
title: "STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295690734.md"
description: "EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T16:26:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295690734.md)
  - [en](https://longbridge.com/en/news/295690734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295690734.md)
generator: "portal-rs"
---

# STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA

EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [STOK.US](https://longbridge.com/en/quote/STOK.US.md)

## Related News & Research

- [Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News](https://longbridge.com/en/news/296264806.md)
- [Moog partners with Voltaic Marine on autonomous unmanned surface vessel development](https://longbridge.com/en/news/296790178.md)
- [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md)
- [Alibaba’s AI Spending Spree Intensifies — Surprise Stock Sale Has Analysts Asking Why](https://longbridge.com/en/news/296767766.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**